PT3038654T - Nova utilização - Google Patents

Nova utilização

Info

Publication number
PT3038654T
PT3038654T PT147617021T PT14761702T PT3038654T PT 3038654 T PT3038654 T PT 3038654T PT 147617021 T PT147617021 T PT 147617021T PT 14761702 T PT14761702 T PT 14761702T PT 3038654 T PT3038654 T PT 3038654T
Authority
PT
Portugal
Prior art keywords
new use
new
Prior art date
Application number
PT147617021T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3038654(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3038654T publication Critical patent/PT3038654T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT147617021T 2013-08-26 2014-08-26 Nova utilização PT3038654T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
PT3038654T true PT3038654T (pt) 2020-02-04

Family

ID=51494327

Family Applications (2)

Application Number Title Priority Date Filing Date
PT147617021T PT3038654T (pt) 2013-08-26 2014-08-26 Nova utilização
PT192028546T PT3626270T (pt) 2013-08-26 2014-08-26 Tratamento de doenças cardiovasculares

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT192028546T PT3626270T (pt) 2013-08-26 2014-08-26 Tratamento de doenças cardiovasculares

Country Status (15)

Country Link
US (2) US20160213646A1 (pt)
EP (3) EP3626270B1 (pt)
JP (1) JP6097888B2 (pt)
CY (1) CY1122531T1 (pt)
DK (2) DK3038654T3 (pt)
ES (2) ES2767084T3 (pt)
FI (1) FI3626270T3 (pt)
HR (2) HRP20240034T1 (pt)
HU (2) HUE064634T2 (pt)
LT (2) LT3038654T (pt)
PL (2) PL3038654T3 (pt)
PT (2) PT3038654T (pt)
RS (2) RS65037B1 (pt)
SI (2) SI3038654T1 (pt)
WO (1) WO2015028941A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562866B2 (en) * 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
EP3302460A1 (en) * 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CA3010778C (en) 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
EP3840746A1 (en) 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN115487175B (zh) * 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Elliptical amino compounds converted by biphenyl process for their preparation and pharmaceutical preparations containing them
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
HUP0000108A2 (hu) * 1997-01-10 2001-04-28 Merck & Co., Inc. Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására
DE60315795T2 (de) * 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP4186491A1 (en) 2007-11-06 2023-05-31 Novartis AG Pharmaceutical compositions
KR20180117734A (ko) 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
EP2608784B1 (en) * 2010-08-24 2018-09-19 Novartis AG Treatment or prevention of heart failure in a mammal receiving anti-coagulant therapy
PL2887961T3 (pl) * 2012-08-24 2021-11-08 Novartis Ag Inhibitory nep do leczenia chorób charakteryzujących się powiększeniem lub przebudową przedsionka
WO2015030711A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use

Also Published As

Publication number Publication date
EP3038654A1 (en) 2016-07-06
US20210077461A1 (en) 2021-03-18
HUE047186T2 (hu) 2020-04-28
LT3626270T (lt) 2024-01-25
JP2016528303A (ja) 2016-09-15
EP4321157A2 (en) 2024-02-14
PL3626270T3 (pl) 2024-04-08
ES2968541T3 (es) 2024-05-10
PT3626270T (pt) 2024-01-11
EP4321157A3 (en) 2024-05-15
HRP20200060T1 (hr) 2020-04-03
SI3626270T1 (sl) 2024-03-29
EP3626270A1 (en) 2020-03-25
RS65037B1 (sr) 2024-02-29
EP3038654B1 (en) 2019-10-30
HUE064634T2 (hu) 2024-04-28
DK3038654T3 (da) 2020-02-03
CY1122531T1 (el) 2021-01-27
FI3626270T3 (fi) 2024-01-11
WO2015028941A1 (en) 2015-03-05
SI3038654T1 (sl) 2020-02-28
LT3038654T (lt) 2020-01-27
US20160213646A1 (en) 2016-07-28
EP3626270B1 (en) 2023-10-11
RS59816B1 (sr) 2020-02-28
DK3626270T3 (da) 2024-01-15
PL3038654T3 (pl) 2020-05-18
HRP20240034T1 (hr) 2024-03-29
ES2767084T3 (es) 2020-06-16
JP6097888B2 (ja) 2017-03-15

Similar Documents

Publication Publication Date Title
PT3626270T (pt) Tratamento de doenças cardiovasculares
GB201305825D0 (en) New use
GB2514689B (en) Quick-Coupler
HK1204451A1 (en) Novel use
AU353576S (en) Stamphousing
GB201321218D0 (en) Novel use
GB201321223D0 (en) Novel use
GB201319828D0 (en) Novel use
GB201319824D0 (en) Novel use
GB201318414D0 (en) Novel use
GB201318415D0 (en) Novel use
GB201321145D0 (en) SuperFoodLX
AU353327S (en) Kettlebell
AU353329S (en) Kettlebell
AU353328S (en) Kettlebell
AU353326S (en) Kettlebell
AU353331S (en) Kettlebell
AU353325S (en) Kettlebell
GB201318786D0 (en) Gtifrsfaapp
AP00812S1 (en) Stumbelbloc
AU2013231V (en) Bonsca7200 Scaevola aemula
GB201315590D0 (en) MyHealthPal
AU353341S (en) Playsuit
AP2013000704S (en) Gramoquat
AP2013000703S (en) Adwura wura